Science NAC 600mg NAC Supplement for Lung Health &
Department of Pharmacy, University of Karachi, Pakistan
Some approved and experimental weight loss drugs Wegovy from Novo Nordisk: Approved weekly injection that activates GLP-1 Zepbound from Eli Lilly: Approved weekly injection that activates GLP-1 and GIP Saxenda from Novo Nordisk: Approved weekly injection that activates GLP-1 MariTide from Amgen: Experimental monthly injection that activates GLP-1 and blocks GIP Danuglipron from Pfizer: Experimental once-daily pill that activates GLP-1 VK2735 from Viking Therapeutics: Experimental weekly injection that activates GLP-1 and GIP Pemvidutide from Altimmune: Experimental weekly injection that activates GLP-1 and another gut hormone called glucagon GSBR-1290 from Structure Therapeutics: Experimental weekly pill that activates GLP-1 Survodutide from Zealand Pharma, Boehringer Ingelheim: Experimental weekly injection that activates GLP-1 and glucagon That appears to contradict how Zepbound works
Future Research Directions To further clarify remaining uncertainty, future research should prioritize: Longer follow-up periods in large, active-comparator cohorts Mandatory histologic subtype linkage in registry studies International collaboration to increase power for rare outcomes like MTC Prospective registries in high-risk populations Transparent reporting of surveillance intensity and imaging utilization Final Conclusions After comprehensive review of mechanistic data, randomized trials, observational cohorts, pharmacovigilance analyses, and expert syntheses, the following conclusions are supported: There is no convincing human evidence that GLP-1 receptor agonists cause papillary, follicular, or Oncocytic (Hrthle cell) thyroid cancers The FDA boxed warning is appropriately narrow, reflecting rodent findings relevant to medullary thyroid carcinoma and MEN2 Apparent associations in some studies are plausibly explained by detection bias, confounding, and outcome misclassification Broad extrapolation of the warning to all thyroid cancers is not scientifically justified Evidence-based, subtype-specific counseling is essential to avoid unnecessary fear and ensure appropriate use of effective therapies This white paper is intended to serve as a durable reference for clinicians, patients, media professionals, and policymakers navigating a complex topic at the intersection of endocrinology, oncology, and public communication
Frequently Asked Questions Can you take NAD+ with Ozempic, Wegovy, or Mounjaro
SURMOUNT-5 Investigators
